Search results
Results from the WOW.Com Content Network
Herpes Simplex, chickenpox, [2] varicella zoster virus: GSK: guanosine analogue RTI 1981 Adefovir: Hepatitis B [3] Gilead Sciences RTI 2002 , 2003 Amantadine: Influenza: Influenza A virus M2 proton channel antagonist 1966 Ampligen: Avian Influenza: Immunomodulatory double-stranded RNA: 2016 Amprenavir (Agenerase) HIV Protease inhibitor (PI ...
Empiric antibiotic therapy should be guided by the most likely source of infection and the patient's past exposure to healthcare facilities. [45] In particular, a recent history of exposure to a healthcare setting may necessitate the need for antibiotics with pseudomonas aeruginosa coverage or broader coverage for resistant organisms. [ 45 ]
Oncolytic virotherapy is not a new idea – as early as the mid 1950s doctors were noticing that cancer patients who suffered a non-related viral infection, or who had been vaccinated recently, showed signs of improvement; [3] this has been largely attributed to the production of interferon and tumour necrosis factors in response to viral infection, but oncolytic viruses are being designed ...
A technology using the synthetic psoralen (amotosalen HCl) and UVA light (320–400 nm) has been implemented in European blood centers for the treatment of platelet and plasma components to prevent transmission of blood-borne diseases caused by bacteria, viruses and protozoa. [13] [14]
BSAs are potential candidates for treatment of emerging and re-emerging viruses, such as ebola, marburg, and SARS-CoV-2. [3] [4] Many BSAs show antiviral activity against other viruses than originally investigated (such as remdesivir and interferon alfa). Efforts in drug repurposing for SARS-CoV-2 is currently underway.
The estimated incidence is 4.5 nosocomial infections per 100 admissions, with direct costs (at 2004 prices) ranging from $10,500 (£5300, €8000 at 2006 rates) per case (for bloodstream, urinary tract, or respiratory infections in immunocompetent people) to $111,000 (£57,000, €85,000) per case for antibiotic-resistant infections in the ...
Antimicrobial use has been common practice for at least 2000 years. Ancient Egyptians and ancient Greeks used specific molds and plant extracts to treat infection. [5]In the 19th century, microbiologists such as Louis Pasteur and Jules Francois Joubert observed antagonism between some bacteria and discussed the merits of controlling these interactions in medicine. [6]
In 2015, the Preventing Antibiotic Resistance Act (PARA) was passed with two components: requirement of drug companies to provide evidence that antibiotics that are approved for use in poultry, and that meat production does not add to the growing threat of antibiotic resistance in humans. [30]